Summary A total of 458 eligible patients, from 21 centres, with histologically or cytologically confirmed SCLC were allocated at random to three chemotherapy regimens, each given at 3-week intervals. In two regimens, etoposide, cyclophosphamide, methotrexate and vincristine were given for a total of either three courses (ECMV3) or six courses (ECMV6). In the third regimen, etoposide and ifosfamide were given for six courses (EI6 It is well established that small cell lung cancer initially responds well to combinations of cytotoxic drugs and radiotherapy, although long-term survival rates are low. The aims of treatment are to control symptoms and prolong survival. Treatment may induce its own morbidity and it is therefore undesirable to continue it for longer than is necessary.
It is well established that small cell lung cancer initially responds well to combinations of cytotoxic drugs and radiotherapy, although long-term survival rates are low. The aims of treatment are to control symptoms and prolong survival. Treatment may induce its own morbidity and it is therefore undesirable to continue it for longer than is necessary.
If the tumour responds, the maximum response, complete or partial (World Health Organization, 1979) , is usually achieved after only two or three courses of chemotherapy. Several randomised trials have therefore attempted to determine the minimum number of courses of chemotherapy that can be given without compromising survival. At the time the present trial was being planned, the Midlands Small Cell Lung Cancer Group (Cullen et al., 1986) were conducting a trial in which patients who achieved a response to induction chemotherapy with six courses of vincristine, doxorubicin, and cyclophosphamide were randomly allocated to a further eight courses of maintenance chemotherapy or to no further chemotherapy until relapse. In a trial by the EORTC (European Organization for Research and Treatment of Cancer) (Splinter, 1988) , patients who responded to five courses of cyclophosphamide, doxorubicin, and etoposide were being randomly allocated to a further seven courses of chemotherapy or symptomatic treatment alone, and in a trial by the London Lung Cancer Group (Harper et al., 1987) , patients were being randomly allocated to eight or four courses of etoposide, cyclophosphamide and vincristine (ECV), and there was a second randomisation to further chemotherapy with doxorubicin and methotrexate or to symptomatic treatment alone at the time of relapse. In a previous trial conducted by the Medical Research Council (MRC Lung Cancer Working Party, 1989) also given megavoltage radiotherapy to a midline dose of 40 Gy in 15 daily fractions over 3 weeks starting 3 weeks after the third course of chemotherapy. It was delivered through planned portals to the primary site and mediastinal lymph nodes, the field extending at least from the suprasternal notch to 3 cm below the carina and encompassing the full width of the mediastinum and lung hila. ECMV6 The ECMV6 regimen comprised six courses of the same chemotherapy as the ECMV3 regimen. Patients with limited disease also received thoracic radiotherapy, as above, after the third course of chemotherapy, the fourth course being given 3 weeks after the end of radiotherapy. EI6 The E16 regimen comprised six courses of chemotherapy, each course given on three consecutive days at 3-week intervals. Etoposide was given as above. On day 1 it was followed by ifosfamide S g m2 plus mesna 5 g m2, mixed together, by intravenous infusion over 24 h. On day 2 the etoposide was followed by mesna 3 g mr2 by intravenous infusion over 12 h. If the etoposide was given orally, the mesna could be given orally, 2 g m-2 being given three times at intervals of 4 h. Patients with limited disease also received the same thoracic radiotherapy as in the ECMV6 regimen, after the third course of chemotherapy, the fourth course being given 3 weeks after the end of radiotherapy.
Reports and investigations
The pretreatment assessment included clinical examination, a postero-anterior chest radiograph, measurement of the blood haemoglobin and plasma urea, creatinine, and bilirubin concentrations, and total white blood cell and platelet counts.
The extent of disease, as assessed on clinical and radiographic evidence, was recorded as either limited to the soft tissues of one hemithorax, the mediastinum and the ipsilateral and contralateral scalene and lower cervical lymph nodes (limited disease), or more extensive than this (extensive disease).
A report was also completed at each attendance for treatment, then monthly up to 12 months and then once every 3 months. These reports included details of the treatment given, the response to treatment, partial or complete (World Health Organization, 1979) , metastases, and the results of the same investigations as were done pretreatment. At death, the certified cause was reported and, if an autopsy was done, the findings.
Assessment ofphysical condition by clinicians The clinician's assessments of the patient's overall condition, performance status and degree of breathlessness were recorded at each attendance according to the categories shown in Table I . The clinician also asked the patient about the occurrence and severity of cough, haemoptysis, chest pain, anorexia, dysphagia, pain in sites other than the chest, and of possible adverse effects of treatment, recording the answers as none, mild, moderate, or severe.
Statistical methods
The Kaplan-Meier estimate was used to calculate survival curves and the Mantel-Cox version of the log-rank test to make treatment comparisons. Survival was calculated from the date of randomisation until death or date last known to be alive. The metastasis-free survival time, in patients with limited disease, was calculated from randomisation until the first appearance of metastases. Patients who died before metastases were detected were censored. Associated confidence intervals (CI) for the corresponding hazard ratios (HR) were calculated as described in Machin and Gardner (1989) . The effect of factors for prognosis on survival was assessed by a proportional hazards regression model as described in, for example, Altman (1991) . The trial data were managed using the COMPACT programme (COMPACT Steering Committee, 1991) .
Results
Patients in the trial Between February 1985 and April 1989, 491 patients (165 ECMV3, 163 ECMV6, 163 E16) were admitted from 21 centres in the United Kingdom. There were 33 patients (8 ECMV3, 11 ECMV6, 14 E16) who were subsequently regarded as ineligible, 24 because the reference histopathologist considered that their histology was not small cell lung cancer and the remaining nine, because they were entered in error: two had had previous malignant disease, two had brain metastases, two had already received treatment, two had been randomised against their consultant clinician's wishes, and one was aged over 75. According to our practice at the time, no follow-up data, other than the date of death, were routinely collected on these 33 patients and they are omitted from all the analyses presented in this report except survival (see Table II ). There remain 458 patients (157 ECMV3, 152 ECMV6, 149 EI6) for analysis.
The characteristics of the patients on admission are shown in Table I . The overall condition, performance status, and degree of breathlessness were normal or nearly normal (grade 0 or 1) in 62%, 63%, and 52%, respectively. In addition, most (84%) of the patients had cough, 31% had haemoptysis, 47% chest pain, 51% anorexia, and 8% dysphagia (Paper 2). The distributions of these variables were similar in the three treatment groups.
Protocol treatment received In all, 296 patients (127 (81%) ECMV3, 84 (55%) ECMV6, 85 (57%) E16) completed their allocated courses of chemotherapy and radiotherapy, although 80 (20 ECMV3, 36 ECMV6, 24 EI6) of them experienced delays, reductions in dosages and/or the omission of one or more drugs because of toxicity. A further 15 patients (five ECMV3, three ECMV6, seven E16) never started their allocated regimen, although three ECMV3 patients were given El and two E16 patients The total response rates were thus 60%, 57% and 67%, respectively. Patients who died during this period were classified as non-responders. Survival Follow-up is complete for all of the 458 eligible patients up to at least 4 years from the date of allocation. The survival comparison by regimen is shown in Figure 1 and is summarised in Table II . The table indicates a small disadvantage for the ECMV3 group compared with the other two, but no evidence of a difference between the ECMV6 and E16 groups (HR = 0.87 and 0.86 respectively compared with ECMV3).
However, the Mantel-Cox test gives X2 = 1.00, df = 2, and P = 0.6, indicating no statistically significant differences between the treatment groups. (See also the analysis summarised in Table III described below.) At 1 year, 24%, 29%, and 30% of patients were alive, and at 2 years 7%, 8%, and 9%, respectively. There was little difference in the median survival times, these being 225 days (7.4 months) in the ECMV3 group, 263 days (8.6 months) in the ECMV6 group and 269 days (8.8 months) in the EI6 group. The small advantage to the 6-course regimens was most evident in patients showing a response to chemotherapy (HR=0.80 and 0.79) than in non-responders (HR = 1.20 and 1.01).
The estimated HRs of Table II were little affected following separate stratified analyses for the known prognostic factors: performance status and extent of disease on admission; albeit, each had prognostic influence on survival. Their individual effects on prognosis, with all three treatment groups combined, are illustrated in Figure 2 . Thus, prognosis clearly reflects the gradient of performance status and patients with extensive disease were at a disadvantage compared with those with limited disease.
These variables, together with the remaining potential prognostic variables recorded at randomisation, were investigated using the Cox proportional hazards model to see if they were of independent importance. Missing data were assigned to a separate category for each variable. This (Figure 2 ) although the respective CIs were wide (Table III) . As expected, patients for whom these variables were not recorded, for whatever reasons, take intermediate positions.
The adjusted HR for the treatment effects and the associated 95% confidence intervals are also indicated in Table III . Even allowing for the above prognostic factors, there was no significant survival benefit for any of the three regimens, nor for six as opposed to three courses of chemotherapy. These conclusions are unaffected if the 33 ineligible patients are included in the survival analysis (Table  II) .
Early death was much more likely to occur in patients with poor performance status pretreatment, especially if they also had extensive disease (Table IV) . Moreover, the times of death were clustered in the second week after the date of start of chemotherapy; 25 of the 41 occurred during that week compared with eight during the first week and eight during the third week.
Cause of death Of the 421 patients (146 ECMV3, 140 ECMV6, 135 EI6) who died within 2 years of randomisation, 407 were certified as having died from their cancer. In a further eight (three ECMV3, two ECMV6, three E16), toxicity was recorded as a major contributing factor. Five (one ECMV3, two ECMV6, two E16) died from other causes, and in the remaining patient (ECMV3) the cause of death was unknown. Data on residual tumour at the primary site were available on 376 patients (130 ECMV3, 125 ECMV6, 121 E16), of whom 89 (68%), 77 (62%), and 74 (61%), respectively, had residual tumour, and of these, 78 (88%), 68 (88%), and 63 (85%) in the three treatment groups respectively, also had distant Figure 2 Percentage of patients surviving from the date of randomisation according to WHO performance status, extent of disease, dysphagia, and blood total white cell count on admission. Total portions in the three treatment groups, although the median time to their first appearance was 177 days in the ECMV3 group compared with 214 and 233 days, or 1 to 2 months later, in the ECMV6 and E16 groups, respectively (X2 = 4.85, df = 2, P = 0.09, Mantel-Cox test).
Discussion
The present trial, involving 458 patients, is one of a number of randomised clinical trials that have recently investigated the optimum duration of chemotherapy in the treatment of small-cell lung cancer. Their aim has been to define the minimum amount of chemotherapy necessary to achieve the best possible effect on survival, thereby keeping the adverse effects of chemotherapy to a minimum. There was no statistically significant survival advantage to any of the treatment groups: etoposide, cyclophosphamide, methotrexate, and vincristine for three courses (ECMV3) or for six courses (ECMV6), or etoposide and ifosfamide for six courses (E16). Nevertheless, the data are not inconsistent with the possibility of a 10% greater death-rate (HR = 1.1) with the three-course regimen compared with the six-course regimens, but to confirm such a difference with the same test size and power would require a randomised comparison involving at least 4,000 patients. The size of the differences was small: I month median survival time, a difference of questionable clinical importance. As in previous trials comparing different treatment durations, the small advantage to the longer duration was most evident in patients showing a response to chemotherapy (MRC Lung Cancer Working Party, 1989; Spiro et al., 1989) . Response rates and the proportions of patients in whom metastases appeared were similar in the three groups although metastases tended to appear sooner in the three-course group than in the six-course groups.
Survival was somewhat shorter than has been reported by some other cooperative groups, but was similar to that in other large national studies. Such studies are probably more representative of the patient population as a whole (reviewed by Hansen, 1992) . The results are also similar to those reported in the comparable trials conducted in the UK. They need to be interpreted together with those from the other comparable trials investigating the optimum duration of chemotherapy. In a previous Medical Research Council trial (MRC Lung Cancer Working Party, 1989) , 265 patients responded to initial chemotherapy with six courses of etoposide, cyclophosphamide, methotrexate, and vincristine, and were then allocated at random to a further six courses of the same chemotherapy or to no further chemotherapy until relapse. There was no evidence of an overall survival advantage to either group. Nevertheless, there was a suggestion that maintenance chemotherapy prolonged survival in patients with a complete response at the time of randomisation.
In the trial conducted by the Midlands Small Cell Lung Cancer Group (Cullen et al., 1986) , 93 patients responded well to induction chemotherapy with six courses of vincristine, doxorubicin, and cyclophosphamide, and were allocated at random to a further eight courses of maintenance chemotherapy or to no further chemotherapy until relapse. Maintenance chemotherapy significantly prolonged survival in the patients with extensive disease on admission, but in the patients with limited disease, survival was longer in the no maintenance group, although this difference was not statistically significant.
The London Lung Cancer Group allocated 616 patients at random to receive either four or eight courses of etoposide, cyclophosphamide, and vincristine, and at relapse to receive either symptomatic treatment or further chemotherapy using drugs other than those used initially. There were thus four patient groups compared. The only survival difference found was that survival was significantly shorter in patients allocated to receive four courses of initial chemotherapy without further chemotherapy on relapse; the difference was greatest in the responding patients, but even this difference was small. The authors concluded that if only four courses of chemotherapy were given, there was a survival disadvantage unless patients received chemotherapy on relapse, but if eight courses were given initially, then there was no advantage from giving further chemotherapy at relapse. They emphasised, however, that the policy of giving chemotherapy on relapse was difficult to apply because patients and physicians were often reluctant to restart chemotherapy.
In the trial undertaken by the EORTC (Giaccone et al., 1993) , 434 patients responded to initial chemotherapy with five courses of cyclophosphamide, doxorubicin, and etoposide, and were then allocated at random to conservative treatment only or a further seven courses of the same chemotherapy. Although the time to progression was significantly prolonged by maintenance chemotherapy, there was no survival advantage to either group.
In the light of all these findings it seems reasonable to conclude that in terms of the duration of survival six courses of chemotherapy should be accepted as a maximum (Spiro & Souhami, 1990) . Nevertheless, an important conclusion, particularly in the light of the comparison of six vs three courses in the present trial, is that current chemotherapy regimens achieve almost all of their potential action during the first three courses. This implies that clinicians should aim to give these three courses without interruption or modification.
In the present trial, a number of characteristics affected prognosis. Poor performance status and extensive disease at the time of randomisation had an adverse influence, confirming findings from previous studies (Rawson & Peto, 1990) . Dysphagia, suggesting a centrally situated tumour or mediastinal extension, had an adverse effect, as did a white blood cell count above 10,000 mm-', suggesting the presence of infection or marrow infiltration. Moreover, the survival curves show that much of the adverse effect of these factors was seen within a month of randomisation. Rawson and Peto included white blood cell count in their analysis but did not have data available on dysphagia or other symptoms. Analyses of prognostic factors need to continue because prognostic indicators not previously investigated may yet be identified. We are also undertaking an updated analysis on data from the trials studied by Rawson and Peto. This will have the advantage of including larger numbers of events and hence of increasing statistical power.
As in earlier trials (MRC Lung Cancer Working Party, 1989; Morittu et al., 1989) , a substantial number of deaths in the present trial occurred shortly after the start of treatment. The times of these deaths were closely clustered in the second week after the date of start of the first course of chemotherapy, the period when the peripheral white blood cell count is likely to have been at its lowest. This also suggests that infection could be an important contributory cause of these early deaths, and that the routine use of prophylactic antibiotics during chemotherapy, especially in patients in the poor prognostic group, could help to prevent them (Morittu et al., 1989) . Such a policy has now been adopted by the MRC Lung Cancer Working Party. Patients with adverse prognostic indicators need close supervision during the early weeks of chemotherapy if these early deaths are to be reduced or avoided. In the present trial (Paper 2) the frequency and severity of adverse effects of treatment were very similar in the three treatment groups. About two thirds of the patients in all three groups were reported by their clinicians to have experienced moderate or severe adverse effects, the commonest of which were anorexia, myelosuppression, dysphagia, and vomiting. Both drug combinations were highly effective in palliating the symptoms of the disease. The proportions of patients with improvement in overall condition, performance status, and breathlessness were somewhat higher in the EI6 than in the two ECMV groups, but this small advantage needs to be weighed against the inconvenience of the 24-h infusions required compared with the 30-min infusions of the ECMV regimens.
The results of this trial support the view that is generally becoming accepted that intensive chemotherapy is indicated for patients in whom tumour control is a realistic mediumterm goal, and that less toxic palliative chemotherapy, or indeed radiotherapy, should be considered for patients with poor performance status and advanced disease (Hansen, 1992) . In line with this policy, the MRC Lung Cancer Working Party is currently investigating the feasibility of dose intensification with haemopoietic growth-factor support in the better prognosis group. In the poor prognosis group, we are investigating the implications for quality of life and survival if the four-drug regimen (ECMV) is reduced to a two-drug regimen of etoposide and vincristine as palliative chemotherapy (LU12 protocol), and are also comparing single-drug orally administered etoposide vs standard intravenous chemotherapy (LU16 protocol). There is still a case for investigating whether patients in the worst prognostic groups should be given any chemotherapy.
